Stocks · News reference
Aurinia Pharmaceuticals Q2 EPS $0.28 Beats $0.24 Estimate, Sales $83.220M Beat $79.357M Estimate
Aurinia Pharmaceuticals (NASDAQ:AUPH) reported quarterly earnings of $0.28 per share which beat the analyst consensus estimate of $0.24 by 16.67 percent. This is a 75 percent increase over earnings of $0.16 per share
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 6, 2026, 12:40 PM
- Checked
- Aug 6, 2026, 12:41 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Aurinia Pharmaceuticals and Teva Settle Patent Dispute for Kidney Disease Drug
Aurinia Pharmaceuticals shares rise after settling patent litigation with Teva, which can launch generic voclosporin no earlier than December 2036.
Read original at benzinga8-K filing — Aurinia Pharmaceuticals Inc. (AUPH)
Filed: 2026-08-19 AccNo: 0001600620-26-000066 Size: 177 KB Item 8.01: Other Events
Read original at edgarAurinia Settles Teva Patent Litigation, Protecting Voclosporin Exclusivity In U.S. Until December 2036 And Affirming Validity Of Key Patents Through 2037
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) today announced that it and its subsidiary, Aurinia Pharma U.S., Inc., (collectively, "Aurinia") have entered into a settlement agreement with Teva Pharmaceuticals Inc.
Read original at benzinga